Amol wants you to:
1. Consider how the evidence helps us decide whether to prescribe a patient warfarin or a novel oral anticoagulant for stroke prevention in atrial fibrillation.
Internists can receive 0.5 hours of Continuing Medical Education credit for each podcast they listen to through the Canadian Society of Internal Medicine (MOC Category 1) and the American Medical Association (PRA Category 1). To receive CME credit for listening to this podcast, please click here to fill out our Evaluation and Impact Assessment Form.
http://www.download.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62343-0/fulltext
http://www.bmj.com/content/350/bmj.h1585
http://www.bmj.com/content/350/bmj.h1857
http://www.ncbi.nlm.nih.gov/pubmed/23562920
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60245-8/abstract
http://www.cbc.ca/radio/tapestry/good-bad-it-s-complicated-1.3120767/hearing-voices-1.3120808
The post Flying Solo: Warfarin vs. New Oral Anticoagulants, what does the evidence say? appeared first on Healthy Debate.